托維妥單抗

托維妥單抗（INN：Tovetumab）是一種抗PDGFRA 單克隆抗體，設計用於治療癌症。^[1]它由MedImmune開發，並試驗用於膠質母細胞瘤和非小細胞肺癌。^[2]對於該藥物的開發於2013年停止。^[3]^[4]

存卡里

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. The AAPS Journal. November 2020, 23 (1): 4. PMID 33210183. S2CID 227067803. doi:10.1208/s12248-020-00523-3 .
^ Tovetumab. AdisInsight. Springer Nature Switzerland AG. [2024-03-01]. （原始內容存檔於2017-11-03）.
^ Williams R. Discontinued in 2013: oncology drugs. Expert Opinion on Investigational Drugs. January 2015, 24 (1): 95–110. PMID 25315907. S2CID 23390614. doi:10.1517/13543784.2015.971154.